Table 2.

Preclinical evidence: role of antibiotics in modulating microbiota and outcomes of IECTs

AntibioticsModelMethodEffects on microbiomeOutcomesRef
Ciprofloxacin, 0.15 g/L
Gentamicin, 0.2 g/L
Bacitracin, 1 g/L
Streptomycin, 2 g/L 
CD19-CAR T cell → BALB/c with CD19+ lymphoma Fed water ad libitum from 29 d before IECT throughout the experiment Not mentioned ↓ Spleen B-cell recovery
↑ Spleen CAR T-cell persistence 
84  
Vancomycin, 0.5 g/L CD19-CAR T cell → BALB/c or B6 with CD19+ tumor cells Fed water ad libitum for the duration of the experiment ↓ α-diversity
↓ Ruminococcaceae
↓ Lachnospiraceae 
↓ Tumor size
↑ Spleen and tumor-infiltrating T cells 
85  
Vancomycin, 1 g/L
Metronidazole, 1 g/L
Cefoxitin, 1 g/L
Gentamicin, 1 g/L 
Marilyn T cells (Y chromosome–targeting TCR T) → male B6 Fed water ad libitum for 2 wk before IECT Gut decontamination ↓ Marilyn T-cell infiltration in the gut
↓ GVHD 
86  
Vancomycin, 1 g/L
Metronidazole, 1 g/L
Cefoxitin, 1 g/L
Gentamicin, 1 g/L 
B6 + Marilyn T cells → female B6D2F1 Fed water ad libitum from 14 d before IECT throughout the experiment ↓ Commensal microbiota ↓ Differentially expanded T-cell clones 87  
Ciprofloxacin, 50 mg/kg per day pmel-1 T cells (melanoma-targeting TCR T) → B6 with melanoma Fed water ad libitum for 2 wk from 2 d before IECT ↓ Microbial translocation in the mesenteric lymph nodes ↑ Tumor size 88  
Ciprofloxacin, 0.15 g/L
Gentamicin, 0.2 g/L
Bacitracin, 1 g/L
Streptomycin, 2 g/L 
HA-targeting CD4+ T cell → BALB/c with CT26HA tumors Fed water ad libitum from 29 d before IECT throughout the experiment Not mentioned ↑ Tumor size 84  
Polymyxin B, 1 mg/kg per day pmel-1 T cells (melanoma-targeting TCR T) → B6 with melanoma Fed water ad libitum for the duration of the experiment Block the biological effect of gram-negative LPS ↑ Tumor size 88  
AntibioticsModelMethodEffects on microbiomeOutcomesRef
Ciprofloxacin, 0.15 g/L
Gentamicin, 0.2 g/L
Bacitracin, 1 g/L
Streptomycin, 2 g/L 
CD19-CAR T cell → BALB/c with CD19+ lymphoma Fed water ad libitum from 29 d before IECT throughout the experiment Not mentioned ↓ Spleen B-cell recovery
↑ Spleen CAR T-cell persistence 
84  
Vancomycin, 0.5 g/L CD19-CAR T cell → BALB/c or B6 with CD19+ tumor cells Fed water ad libitum for the duration of the experiment ↓ α-diversity
↓ Ruminococcaceae
↓ Lachnospiraceae 
↓ Tumor size
↑ Spleen and tumor-infiltrating T cells 
85  
Vancomycin, 1 g/L
Metronidazole, 1 g/L
Cefoxitin, 1 g/L
Gentamicin, 1 g/L 
Marilyn T cells (Y chromosome–targeting TCR T) → male B6 Fed water ad libitum for 2 wk before IECT Gut decontamination ↓ Marilyn T-cell infiltration in the gut
↓ GVHD 
86  
Vancomycin, 1 g/L
Metronidazole, 1 g/L
Cefoxitin, 1 g/L
Gentamicin, 1 g/L 
B6 + Marilyn T cells → female B6D2F1 Fed water ad libitum from 14 d before IECT throughout the experiment ↓ Commensal microbiota ↓ Differentially expanded T-cell clones 87  
Ciprofloxacin, 50 mg/kg per day pmel-1 T cells (melanoma-targeting TCR T) → B6 with melanoma Fed water ad libitum for 2 wk from 2 d before IECT ↓ Microbial translocation in the mesenteric lymph nodes ↑ Tumor size 88  
Ciprofloxacin, 0.15 g/L
Gentamicin, 0.2 g/L
Bacitracin, 1 g/L
Streptomycin, 2 g/L 
HA-targeting CD4+ T cell → BALB/c with CT26HA tumors Fed water ad libitum from 29 d before IECT throughout the experiment Not mentioned ↑ Tumor size 84  
Polymyxin B, 1 mg/kg per day pmel-1 T cells (melanoma-targeting TCR T) → B6 with melanoma Fed water ad libitum for the duration of the experiment Block the biological effect of gram-negative LPS ↑ Tumor size 88  

↑ represents increase and ↓ decrease.

LPS, lipopolysaccharides; Ref, reference.

or Create an Account

Close Modal
Close Modal